Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 265 of the 271 references it cites were found in a registry or an index; 87 of the 187 sources its claims cite were checked for support.

Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer

Open access
Colucci-D’Amato, Luca, Speranza, Luisa, Volpicelli, Floriana · 2020 · International Journal of Molecular Sciences

Abstract

Brain-derived neurotrophic factor (BDNF) is one of the most distributed and extensively studied neurotrophins in the mammalian brain. BDNF signals through the tropomycin receptor kinase B (TrkB) and the low affinity p75 neurotrophin receptor (p75NTR). BDNF plays an important role in proper growth, development, and plasticity of glutamatergic and GABAergic synapses and through modulation of neuronal differentiation, it influences serotonergic and dopaminergic neurotransmission. BDNF acts as paracrine and autocrine factor, on both pre-synaptic and post-synaptic target sites. It is crucial in the transformation of synaptic activity into long-term synaptic memories. BDNF is considered an instructive mediator of functional and structural plasticity in the central nervous system (CNS), influencing dendritic spines and, at least in the hippocampus, the adult neurogenesis. Changes in the rate of adult neurogenesis and in spine density can influence several forms of learning and memory and can contribute to depression-like behaviors. The possible roles of BDNF in neuronal plasticity highlighted in this review focus on the effect of antidepressant therapies on BDNF-mediated plasticity. Moreover, we will review data that illustrate the role of BDNF as a potent protective factor that is able to confer protection against neurodegeneration, in particular in Alzheimer's disease. Finally, we will give evidence of how the involvement of BDNF in the pathogenesis of brain glioblastoma has emerged, thus opening new avenues for the treatment of this deadly cancer.

Overview

CoChat Summary

TL;DR

This review summarizes BDNF signaling through TrkB and p75NTR and its roles in synaptic plasticity, adult neurogenesis, depression, neurodegeneration, and glioblastoma. It argues that BDNF is a key mediator of antidepressant and exercise effects and a potential therapeutic target, though clinical translation remains uncertain.

Key findings

  • BDNF is synthesized as preproBDNF (32–35 kDa), cleaved to proBDNF (28–32 kDa), then mature mBDNF (13 kDa); proBDNF and mBDNF can exert opposing effects via p75NTR and TrkB, respectively.
  • The human BDNF gene has 11 exons and nine alternative promoters; the Val66Met polymorphism (rs6265) impairs activity-dependent BDNF secretion and has been linked to mood disorders, cognitive/neurodegenerative phenotypes, but replication is inconsistent.
  • In major depressive disorder, BDNF mRNA and protein are decreased in hippocampus, prefrontal cortex, and amygdala; antidepressants increase BDNF/TrkB signaling in rodent cortex and hippocampus. Three months of aerobic exercise training increased hippocampal volume by 12% in healthy individuals and 16% in patients with schizophrenia.
  • In Alzheimer’s disease, BDNF is reduced and can correlate with disease severity; mouse studies indicate exercise-induced protection requires both adult hippocampal neurogenesis and BDNF. In glioblastoma, BDNF/TrkB can promote tumor growth, but enriched environment/BDNF can also be oncolytic via IL-15/IFN-γ and TrkB.T1.

Methods

  • Narrative review; no primary experiments. It synthesizes published literature on BDNF gene structure, transcripts, miRNAs, signaling, Val66Met, depression, neurodegeneration, and brain cancer.
  • Evidence discussed includes rodent models, in vitro cell studies, human postmortem brain tissue, serum/platelet BDNF measures, genetic association studies, and meta-analyses.
  • No systematic search strategy, inclusion criteria, or quantitative synthesis is reported.

Limitations

  • The paper states that human neuroplasticity remains largely indirect because of methodological limitations and ethical constraints, and that there is no evidence that serum BDNF is related to brain BDNF and neuroplasticity.
  • The paper states that Val66Met genetic findings are inconsistent, with failed replications possibly due to environmental factors, ethnicity, age, and sex.
  • Evident from the text: as a narrative review, it lacks systematic search and quality appraisal; many mechanistic claims rely on rodent or in vitro models, and causal direction in human disease remains uncertain.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms21207777

Cites

265 of 265 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Brain-derived neurotrophic factor (BDNF) protein structure. The preproBDNF consists of three sequences: signal sequence (s.s), pro-domain, and mature domain. The intra- or extracellular cleavage of preproBDNF generates functionally active isoforms: BDNF pro-peptide and mature BDNF (mBDNF), each of which exhibits a characteristic affinity to a specific type of receptor. Arrowheads indicate known protease cleavage sites involved in the processing of mature BDNF. The position of the single nucleotide polymorphism (rs6265, Val66Met) and the substitution of valine (Val) in methionine (Met) at codon (aa) 66 in the human BDNF gene is indicated by an arrow.
Figure 1 Brain-derived neurotrophic factor (BDNF) protein structure. The preproBDNF consists of three sequences: signal sequence (s.s), pro-domain, and mature domain. The intra- or extracellular cleavage of preproBDNF generates functionally active isoforms: BDNF pro-peptide and mature BDNF (mBDNF), each of which exhibits a characteristic affinity to a specific type of receptor. Arrowheads indicate known protease cleavage sites involved in the processing of mature BDNF. The position of the single nucleotide polymorphism (rs6265, Val66Met) and the substitution of valine (Val) in methionine (Met) at codon (aa) 66 in the human BDNF gene is indicated by an arrow.CC BY · PubMed Central
Figure 2 Intracellular signaling cascades activated by interaction of BDNF isoforms with its receptors. proBDNF and mBDNF bind to different receptors, respectively. The mBDNF isoform exhibits highest affinity for the tyrosine kinase B receptor (TrkB) receptor, which when stimulated undergoes homodimerization and autophosphorylation, but also binds the low affinity neurotrophin receptor p75NTR. The interaction between the TrkB receptor and the p75NTR receptor in a complex increases the ligand binding affinity to BDNF. Sortilin is considered a co-receptor for p75NTR. The proBDNF isoform, consisting of two sequences (pro-domain and mature domain), interacts with specific receptors, sortilin and p75NTR, respectively. The binding of proBDNF to a p75NTR/sortilin-complex induces signaling pathways that are specific for proBDNF. The binding of proBDNF in combination with sortilin causes the involvement of neurotrophin receptor-interacting factor (NRIF), tumor necrosis factor receptor-associated factor 6 (TRAF6), and neurotrophin receptor-interacting MAGE homologue (NRAGE) proteins. This pathway activates the JNK-associated pathway that promotes programmed cell death, or the receptor-interacting serine/threonine-protein kinase 2 (RIP2) /TRAF6-mediated pathway is initiated. Multi-subunit IκB kinase (IKK) phosphorylates (orange dot) the inhibitor of kB (IkB) protein, which results in dissociation of IkB from NF-κB. The activated nuclear factor kappa B (NF-kB) is then translocated into the nucleus where it binds to specific sequences of DNA and promotes neuronal survival and maintenance. In addition, p75NTR interacts with the Rho family of proteins, whose activation mediates the activity of Rho-associated protein kinase (ROCK), which subsequently leads to activation of the AKT pathway, involved in cytoskeletal remodeling. The mBDNF/TrkB receptor complex triggers signaling pathways associated with activation of phosphatidylinositol 3-kinase (PI3K), phospholipase C gamma (PLC-γ), and GTP-ases of the Rho family, involved in survival, plasticity and neurite outgrowth, transcription regulation, and synaptic plasticity.
Figure 2 Intracellular signaling cascades activated by interaction of BDNF isoforms with its receptors. proBDNF and mBDNF bind to different receptors, respectively. The mBDNF isoform exhibits highest affinity for the tyrosine kinase B receptor (TrkB) receptor, which when stimulated undergoes homodimerization and autophosphorylation, but also binds the low affinity neurotrophin receptor p75NTR. The interaction between the TrkB receptor and the p75NTR receptor in a complex increases the ligand binding affinity to BDNF. Sortilin is considered a co-receptor for p75NTR. The proBDNF isoform, consisting of two sequences (pro-domain and mature domain), interacts with specific receptors, sortilin and p75NTR, respectively. The binding of proBDNF to a p75NTR/sortilin-complex induces signaling pathways that are specific for proBDNF. The binding of proBDNF in combination with sortilin causes the involvement of neurotrophin receptor-interacting factor (NRIF), tumor necrosis factor receptor-associated factor 6 (TRAF6), and neurotrophin receptor-interacting MAGE homologue (NRAGE) proteins. This pathway activates the JNK-associated pathway that promotes programmed cell death, or the receptor-interacting serine/threonine-protein kinase 2 (RIP2) /TRAF6-mediated pathway is initiated. Multi-subunit IκB kinase (IKK) phosphorylates (orange dot) the inhibitor of kB (IkB) protein, which results in dissociation of IkB from NF-κB. The activated nuclear factor kappa B (NF-kB) is then translocated into the nucleus where it binds to specific sequences of DNA and promotes neuronal survival and maintenance. In addition, p75NTR interacts with the Rho family of proteins, whose activation mediates the activity of Rho-associated protein kinase (ROCK), which subsequently leads to activation of the AKT pathway, involved in cytoskeletal remodeling. The mBDNF/TrkB receptor complex triggers signaling pathways associated with activation of phosphatidylinositol 3-kinase (PI3K), phospholipase C gamma (PLC-γ), and GTP-ases of the Rho family, involved in survival, plasticity and neurite outgrowth, transcription regulation, and synaptic plasticity.CC BY · PubMed Central
Figure 3 The molecular mechanisms mediated by BDNF involved in depression, Alzheimer’s disease, and glioma. External stimuli (stress, maternal deprivation, or lack of activity) causing epigenetic regulation processes can induce a reduction in BDNF expression level and in neuronal activity. This results in atrophy, neuronal death, and cognitive decline, which may contribute to depression or Alzheimer’s disease. In these pathologies the BDNF/TrkB signaling, which activates the downstream Akt and ERK signaling, is altered. Thus, such alterations cause an impairment of CREB signaling resulting in BDNF downregulation. The alteration of phosphorylation (P) inhibits (red X) the transcriptional machinery. In the mouse brain, environmental enrichment induces an increase of BDNF. BDNF, binding the truncated form of TrkB receptor (TrkB.T1), signals directly to the Rho protein dissociation inhibitor (GDI). The latter detaches from TrkB.T1 and binds to the small G protein RhoA, leading to an inhibition of glioma cell migration. BDNF stimulates also indirectly the production of IL-15 in microglia, which in turn stimulates the natural killer cells to produce IFN-γ. IFN-γ contributes to reducing glioma growth.
Figure 3 The molecular mechanisms mediated by BDNF involved in depression, Alzheimer’s disease, and glioma. External stimuli (stress, maternal deprivation, or lack of activity) causing epigenetic regulation processes can induce a reduction in BDNF expression level and in neuronal activity. This results in atrophy, neuronal death, and cognitive decline, which may contribute to depression or Alzheimer’s disease. In these pathologies the BDNF/TrkB signaling, which activates the downstream Akt and ERK signaling, is altered. Thus, such alterations cause an impairment of CREB signaling resulting in BDNF downregulation. The alteration of phosphorylation (P) inhibits (red X) the transcriptional machinery. In the mouse brain, environmental enrichment induces an increase of BDNF. BDNF, binding the truncated form of TrkB receptor (TrkB.T1), signals directly to the Rho protein dissociation inhibitor (GDI). The latter detaches from TrkB.T1 and binds to the small G protein RhoA, leading to an inhibition of glioma cell migration. BDNF stimulates also indirectly the production of IL-15 in microglia, which in turn stimulates the natural killer cells to produce IFN-γ. IFN-γ contributes to reducing glioma growth.CC BY · PubMed Central

Verification

Claims the paper makes

59 Valid · 7 Not valid · 51 Not checked · 18 Own results and interpretations

75 more claims · 23 with their cited sources checked

Create a free account to see all 135 claims and to verify the 25 references still open.

See all claims — free account
  • It may state two separate claims as one. 47
  • Probably not a substantial claim. 14

Create a free account to see these claims.

Citations

Cites

Show all 271 references

Cited by

See all 994

Metadata

Authors
Colucci-D’Amato, L., Speranza, L., & Volpicelli, F.
Affiliations
  • University of Campania "Luigi Vanvitelli" (IT)
  • Albert Einstein College of Medicine (US)
  • University of Naples Federico II (IT)
Corresponding author
Colucci-D’Amato, Luca
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-10-21
Volume
21
Issue
20
Pages
7777
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3094053673
Cited by
991
References
271
Citations by year
2026: 149 · 2025: 251 · 2024: 230 · 2023: 187 · 2022: 122 · 2021: 49 · 2020: 3
FWCI
12.52
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
brain-derived neurotrophic factor, TrkB receptor, p75 neurotrophin receptor, neuroplasticity, synaptic plasticity, dendritic spines, adult neurogenesis, hippocampus, depression, antidepressant treatment, neurodegeneration, Alzheimer's disease, glioblastoma, neuroprotection, learning and memory
MeSH terms
Animals, Antidepressive Agents, Brain Neoplasms, Depression, Humans, Neuronal Plasticity, Oncogenes, Genes, Tumor Suppressor, Neuroprotective Agents, Brain-Derived Neurotrophic Factor, Neurodegenerative Diseases, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer. https://app.cochat.ai/papers/10.3390/ijms21207777
The paper
Colucci-D’Amato, L., Speranza, L., & Volpicelli, F. (2020). Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21207777

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.